COMP <GO>
DGX vs ILMN // FORWARD P/E MULTIPLE
Quest Diagnostics Incorporated (NYSE) VS. Illumina Inc. (NASDAQ) • 15-METRIC TALLY: DGX 6
— ILMN 7
▲ FORWARD P/E MULTIPLE LEADER: DGX
LAST: $250.81 (-0.40%) • MKT CAP: $27.71B
forward-pe
26.1x
LAST: $226.58 (-3.99%) • MKT CAP: $35.63B
forward-pe
47.9x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DGX VS. ILMN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DGX | ILMN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 33.20% | 66.10% | -32.90 | ILMN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.30% | 18.20% | -7.90 | ILMN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.3x | 47.5x | -31.20 | DGX | /valuation <GO> |
| Free Cash Flow Yield | 4.88% | 2.13% | +2.75 | DGX | /fcf-yield <GO> |
| Operating Margin | 14.10% | 18.60% | -4.50 | ILMN | /operating-margins <GO> |
| Net Profit Margin | 9.00% | 19.60% | -10.60 | ILMN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.80% | -0.70% | +12.50 | DGX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.27% | 0.00% | +1.27 | DGX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.01 | 9.52 | -5.51 | ILMN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.9 | 42.3 | +24.60 | DGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 1.16 | -0.15 | ILMN | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 26.1x | 47.9x | -21.80 | DGX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.71B | $35.63B | -$7.93B | ILMN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DGX REV | ILMN REV | DGX GROSS % | ILMN GROSS % | DGX FCF | ILMN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $11.04B | $4.34B | 33.2% | 66.1% | $1.36B | $931.0M |
| FY 2024 | $9.87B | $4.37B | 32.9% | 65.4% | $909.0M | $709.0M |
| FY 2023 | $9.25B | $4.50B | — | — | $855.7M | $275.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DGX // BETA 1.01
ILMN // BETA 1.16